Abstract PO1-19-10: Durvalumab + Datopotamab Deruxtecan in Patients with PD-L1 Positive Advanced/metastatic Triple-Negative Breast Cancer: Arm 8 of the Phase 1b/2, Open Label, Platform BEGONIA Study
Cancer Research（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined